<span item_type="fundamental" item_id="5db727946015c000b6c134908cd2edbc" counter_id="ST/US/GRCE" env="prod"></span><span item_type="announcement" item_id="548587769581932801" env="prod"></span><p>EPS: As of FY2026 Q1, the actual value is USD -0.21.</p><p></p><h3>Segment Revenue</h3><ul><li>Grace Therapeutics, Inc. did not report any revenue for the three months ended June 30, 2025, as the company is still in the development stage and has not yet commercialized any products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $3,362 for the three months ended June 30, 2025, compared to a net loss of $2,617 for the same period in 2024, representing an increase in net loss by $745.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li><li><strong>Research and Development Expenses</strong>: These expenses decreased significantly from $2,708 in the three months ended June 30, 2024, to $955 in the same period in 2025, primarily due to the completion of the GTx-104 pivotal Phase 3 STRIVE-ON safety clinical trial.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li><li><strong>General and Administrative Expenses</strong>: These expenses were $2,135 for the three months ended June 30, 2025, a decrease from $2,255 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: The company used $1,801 in net cash for operating activities during the three months ended June 30, 2025, compared to $3,596 in the same period in 2024, reflecting a decrease in cash used by $1,795.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li><li><strong>Net Cash Used in Investing Activities</strong>: There were no investing activities for the three months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li><li><strong>Net Cash Used in Financing Activities</strong>: The company used $327 in net cash for financing activities during the three months ended June 30, 2025, related to the payment of stock issuance costs in connection with the 2025 Private Placement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Derivative Warrant Liabilities</strong>: The change in fair value of derivative warrant liabilities was a loss of $487 for the three months ended June 30, 2025, compared to a gain of $1,395 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Grace Therapeutics plans to prioritize the development of its lead product candidate, GTx-104, and has submitted a New Drug Application (NDA) to the FDA. The company aims to commercialize GTx-104 with a targeted hospital-based sales force if approved.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li><li><strong>Non-Core Business</strong>: The development of GTx-102 and GTx-101 will be pursued when additional funding is secured or through strategic partnerships. The company may also consider licensing or selling these drug candidates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1444192/000114036125030398/ef20050972_10q.htm"></span></li></ul>

Grace Therapeutics | 10-Q: FY2026 Q1 EPS: USD -0.21